Cure My Disease

Don't miss your cure!

 Log in / Sign up

New study aims to find best stitching technique for kidney cancer surgery

NCT ID NCT07190638

Disease control Sponsor: Brazilian Institute of Robotic Surgery Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study compares two stitching methods used during robot-assisted kidney cancer surgery to see which one better preserves kidney function and reduces blood loss. About 80 adults with kidney cancer will be randomly assigned to receive either a simpler stitch (medullary-only) or a combined stitch (cortical and medullary). The goal is to find the safest and most effective approach for patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jul 2025

Expected to finish

May 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Diagnosis of renal mass confirmed by computed tomography (CT) or magnetic resonance imaging (MRI) * Indication for partial nephrectomy * Written informed consent * Expected survival of at least 6 months * Eastern Cooperative Oncology Group (ECOG) score performance status ≤ 1 * Negative serum or urine pregnancy test within 24 hours before surgery for women of childbearing potential * Recovery from any prior therapy-related toxicity to grade 1 or better * If a biopsy has been performed, pathology consistent with renal cell carcinoma (RCC) Exclusion Criteria: * Solitary kidney * Multiple or bilateral renal masses if more than one mass is operated on simultaneously or within less than 4 months * Hepatic or renal toxicity grade ≥ 2 with glomerular filtration rate (GFR) \< 30 according to Common Terminology Criteria for Adverse Events (CTCAE v4) * Bleeding diathesis * Inability to maintain anticoagulation for surgery * Participation in another experimental trial simultaneously or within 30 days prior to enrollment * Significant acute or chronic medical, neurological, or psychiatric condition that could compromise safety, limit study completion, or impair study objectives in the opinion of the Principal Investigator

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for RCC, renal cell cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

renal cell carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

RCC, renal cell cancer

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    2 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Brazilian Institute of Robotic Surgery

    RECRUITING

    Salvador, Estado de Bahia, 43017030, Brazil

  • Hospital MaterDei Salvador

    RECRUITING

    Salvador, Estado de Bahia, 40220-005, Brazil

More trials for these conditions

Other studies related to the condition(s) this trial covers.